Fewer than one in 10 patients eligible to benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it releases its inaugural guidance on the therapies.
Given over a billion people worldwide currently living with obesity, it is urging increased and just availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be addressed with holistic and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are major barriers to broad access to the treatments that can help people shift considerable body mass, explains the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic case, the supply of such drugs might only reach around 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice urges governments and firms to increase availability, via approaches such as licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
How Obesity Jabs Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so individuals eat less.
People usually see weight reduction after several weeks of starting on the weekly injections.
Research points to users may see weight return a year later of stopping the treatment, when their typical appetite come back.
Being carrying excess weight elevates your likelihood for developing health problems, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts people in all nations and was responsible for millions of deaths worldwide in 2024, as per the WHO.
